Drug Profile
Research programme: cancer therapeutics - Merck & Co/Beryllium
Latest Information Update: 20 Jan 2020
Price :
$50
*
At a glance
- Originator ArQule; Beryllium
- Developer Beryllium; Merck & Co
- Class Small molecules
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; Programmed cell death-1 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Cancer
Most Recent Events
- 16 Jan 2020 ArQule has been acquired and merged into Merck & Co
- 04 Nov 2016 ArQule and Beryllium jointly terminate the research and development agreement for programmed cell death protein and ligand inhibitors in Cancer (ArQule's form 10-K, filed in March 2017)
- 04 Nov 2016 Discontinued for Cancer in USA, as the agreement between the companies was terminated (ArQule's form 10-K, filed in March 2017)